Ionis Pharmaceuticals, Inc.

The stock is still in a major downtrend, trading well below its 200-day average after a long slide from the 52-week high. The setup is closer to a deep reset than a breakout, with price sitting in the lower half of the yearly range rather than near prior highs.

Street sentiment remains constructive, with a Buy consensus and an average target around $95. Recent calls have turned more cautious, with multiple target cuts in July and one downgrade to Peer Perform, but the target stack still sits well above the current share price.

The company has a strong recent beat streak, going 7-for-7 on reported quarters, including a 61.0% EPS beat in the latest completed period. Next quarter expectations remain negative at -$1.11 EPS, so shareholders should watch for continued execution and any improvement in the loss profile.

Recent insider activity leans to net selling, led by discretionary sales from the CSO, a director, and an EVP of development. Several award, exempt, and other non-discretionary transactions also appeared, which are mostly compensation-related noise rather than a clear conviction signal.

Profitability remains weak, with a -47.7% operating margin and a -30.9% net margin. Revenue growth is strong at 87% year over year, but free cash flow was negative $217.1 million and EPS TTM sits at -2.01, so the business is still scaling into earnings.

IONS stands out as a commercial-stage RNA platform with multiple marketed drugs and a deep rare-disease pipeline, which supports a premium profile versus many biotech peers. Even so, the valuation still reflects a loss-making model, with the stock trading below the analyst consensus target and near a sector-risk discount.